News
CORONA Remedies Acquires Wokadine® in India, Strengthens Healthcare Portfolio
CORONA Remedies Limited has announced the acquisition of Wokadine® from Dr. Reddy’s Laboratories, marking a significant step in its growth strategy. The deal, effective March 30, 2026, represents CORONA’s fifth acquisition and reinforces its focus on expanding its footprint in India’s pharmaceutical sector.
This move aligns with the company’s broader vision of enhancing patient care and strengthening its presence in core therapeutic areas.
Entry into the Povidone Iodine Market
With the acquisition of Wokadine®, CORONA Remedies enters the ₹648 crore ($69 Million) povidone iodine market in India. Wokadine® is currently ranked among the top brands in this segment and carries a legacy of over 46 years in antiseptic care.
The product portfolio includes 14 SKUs designed for multiple clinical applications, making it a trusted choice among surgeons, ENT specialists, general physicians, and gynaecologists.
Strengthening Market Presence and Distribution
CORONA Remedies plans to leverage its extensive pan-India distribution network and strong relationships with healthcare professionals to expand Wokadine®’s reach. The company aims to make the product widely accessible across metro cities, semi-urban regions, and rural markets.
This strategic integration is expected to boost brand visibility and ensure consistent availability of essential antiseptic solutions to patients nationwide.
Leadership Perspective on Growth Strategy
According to company leadership, the acquisition reflects CORONA Remedies’ balanced approach to growth through both organic expansion and strategic acquisitions.
Tejas Kothari, Vice President – Corporate Strategy & Business Development, emphasized that the company is focused on strengthening its portfolio by leveraging its trusted reputation among doctors and its robust sales and marketing capabilities.
He added that the acquisition is expected to accelerate growth while deepening engagement with the medical community.
Synergy with Existing Therapeutic Areas
The addition of Wokadine® complements CORONA Remedies’ existing therapeutic focus areas, creating synergies that enhance its overall product offering. By integrating a well-established brand into its portfolio, the company is positioned to deliver comprehensive healthcare solutions.
The acquisition also strengthens CORONA’s equity among key medical specialties, further solidifying its standing in the healthcare ecosystem.
The deal has been fully funded through internal accruals and cash reserves, reflecting the company’s strong financial position. Analysts view this acquisition as a strategic move to unlock new growth opportunities while maintaining financial discipline.
As the demand for antiseptic and infection-prevention solutions continues to grow, CORONA Remedies is well-positioned to capitalize on this expanding market.
The acquisition of Wokadine® marks a pivotal moment for CORONA Remedies as it continues to scale its operations and diversify its portfolio. By entering the povidone iodine segment and leveraging a trusted brand, the company is set to enhance its market presence and deliver greater value to healthcare providers and patients alike.
